Increased Serum APRIL Differentially Correlates with Distinct Cytokine Profiles and Disease Activity in Systemic Lupus Erythematosus Patients

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2014 Apr 22

PMID 24748505

Citations 11

Authors

Ghada Boghdadi

Enass A Elewa

Affiliations

Soon will be listed here.

Abstract

Cytokines play an important role in the pathogenesis of systemic lupus erythematosus (SLE). Among the cytokines that regulate B cell homeostasis is a proliferation-inducing ligand (APRIL). This study aimed to determine whether serum levels of APRIL are raised in patients with SLE and correlate with disease activity or proinflammatory cytokines production, or both. Serum APRIL, interleukin-17 (IL-17), IL-4 and interferon gamma (IFN-γ) levels were measured in forty patients with SLE and 30 healthy controls. Disease activity was assessed by SLE disease activity index (SLEDAI), and results were correlated with serum APRIL levels. Serum APRIL levels were significantly higher in patients with SLE than in healthy controls. Positive correlation was found between serum APRIL levels and total SLEDAI score and anti-dsDNA antibody titers. Moreover, serum APRIL levels was significantly higher in patients with arthritis, mucocutaneous manifestations and proteinuria. APRIL is increased in patients with active SLE accompanying the increase of IL-17 and IFN-γ. Significant positive correlations between serum levels of APRIL and IL-17 and IFN-γ and a negative correlation between serum levels of APRIL and IL-4 were found. The results suggest that APRIL may be an important marker of disease activity in patients with SLE. We provide the analyses of APRIL levels in patients with SLE, suggesting new tools for the diagnosis, prognosis and possible therapeutic management of SLE.

Citing Articles

Anti-inflammatory role of APRIL by modulating regulatory B cells in antigen-induced arthritis.

Carvalho-Santos A, Kuhnert L, Hahne M, Vasconcellos R, Carvalho-Pinto C, Villa-Verde D PLoS One. 2024; 19(5):e0292028.

PMID: 38691538 PMC: 11062543. DOI: 10.1371/journal.pone.0292028.

TNF Superfamily and ILC2 Activation in Asthma.

Matsuyama T, Salter B, Fard N, Machida K, Sehmi R Biomolecules. 2024; 14(3).

PMID: 38540714 PMC: 10967788. DOI: 10.3390/biom14030294.

Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy.

Idborg H, Oke V Int J Mol Sci. 2021; 22(21).

PMID: 34768756 PMC: 8582965. DOI: 10.3390/ijms222111327.

Serum proteome profiles to differentiate Crohn disease from intestinal tuberculosis and primary intestinal lymphoma: A pilot study.

Ning L, Shan G, Sun Z, Lou X, Zhang F, Li S Medicine (Baltimore). 2019; 98(50):e18304.

PMID: 31852111 PMC: 6922555. DOI: 10.1097/MD.0000000000018304.

Delayed onset of autoreactive antibody production and M2-skewed macrophages contribute to improved survival of TACI deficient MRL-Fas/Lpr mouse.

Liu L, Allman W, Coleman A, Takeda K, Lin T, Akkoyunlu M Sci Rep. 2018; 8(1):1308.

PMID: 29358664 PMC: 5778001. DOI: 10.1038/s41598-018-19827-8.

References

Litinskiy M, Nardelli B, Hilbert D, He B, Schaffer A, Casali P . DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002; 3(9):822-9. PMC: 4621779. DOI: 10.1038/ni829. View

Marsters S, Yan M, Pitti R, Haas P, Dixit V, Ashkenazi A . Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol. 2000; 10(13):785-8. DOI: 10.1016/s0960-9822(00)00566-2. View

Hegazy M, Darwish H, Darweesh H, El-Shehaby A, Emad Y . Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. Clin Immunol. 2010; 135(1):118-24. DOI: 10.1016/j.clim.2009.12.012. View

Stohl W, Metyas S, Tan S, Cheema G, Oamar B, Xu D . B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003; 48(12):3475-86. DOI: 10.1002/art.11354. View

Kavanaugh A, Solomon D . Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum. 2002; 47(5):546-55. DOI: 10.1002/art.10558. View

Xiao Y, Motomura S, Podack E . APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response. Eur J Immunol. 2008; 38(12):3450-8. PMC: 2755626. DOI: 10.1002/eji.200838640. View

Krivosikova M, Dallos T, Maslinski W, Buc M . B cell activating factor, its role in autoimmunity, and targeting in autoimmune diseases. Bratisl Lek Listy. 2009; 110(3):137-45. View

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

Treamtrakanpon W, Tantivitayakul P, Benjachat T, Somparn P, Kittikowit W, Eiam-Ong S . APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Arthritis Res Ther. 2012; 14(6):R252. PMC: 3674621. DOI: 10.1186/ar4095. View

10.

Chun H, Chung J, Kim H, Yun J, Jeon J, Ye Y . Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007; 27(5):461-6. DOI: 10.1007/s10875-007-9104-0. View

11.

Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer J . APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998; 188(6):1185-90. PMC: 2212534. DOI: 10.1084/jem.188.6.1185. View

12.

Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner Q, Cachero T . Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med. 2005; 201(9):1375-83. PMC: 2213192. DOI: 10.1084/jem.20042309. View

13.

Seyler T, Park Y, Takemura S, Bram R, Kurtin P, Goronzy J . BLyS and APRIL in rheumatoid arthritis. J Clin Invest. 2005; 115(11):3083-92. PMC: 1257539. DOI: 10.1172/JCI25265. View

14.

Jonsson M, Szodoray P, Jellestad S, Jonsson R, Skarstein K . Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol. 2005; 25(3):189-201. DOI: 10.1007/s10875-005-4091-5. View

15.

Cook R, Gladman D, Pericak D, Urowitz M . Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol. 2000; 27(8):1892-5. View

16.

Adhya Z, Borozdenkova S, Karim M . The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis. Nephrol Dial Transplant. 2011; 26(10):3273-80. DOI: 10.1093/ndt/gfq860. View

17.

Thompson J, Bixler S, Qian F, Vora K, Scott M, Cachero T . BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001; 293(5537):2108-11. DOI: 10.1126/science.1061965. View

18.

Gross J, Johnston J, Mudri S, Enselman R, Dillon S, Madden K . TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000; 404(6781):995-9. DOI: 10.1038/35010115. View

19.

Tan S, Xu D, Roschke V, Perry J, Arkfeld D, Ehresmann G . Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 2003; 48(4):982-92. DOI: 10.1002/art.10860. View

20.

Schneider P, Mackay F, Steiner V, Hofmann K, Bodmer J, Holler N . BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999; 189(11):1747-56. PMC: 2193079. DOI: 10.1084/jem.189.11.1747. View